By using our site you consent to the CTFN Privacy Policy, Cookies Policy, and Terms of Service.


EQT’s Raised Offer for Karo Still Facing Some Resistance

On January 2, EQT increased its offer for Karo Pharma from SEK 36.90 per share to SEK 38.00. EQT succeeded in garnering 29.1% of the shares via acceptances of the original offer, and had purchased 19.3% outside of the offer, taking its potentialfeatured

Strong Demand Likely for Shire/Takeda Divestiture of SHP647

On October 26 Takeda announced it had proposed a remedy to the European Commission of selling Shire’s SHP647, a pipeline compound for the treatment of inflammatory bowel disease, which will potentially compete with Takeda’s marketedfeatured

High Likelihood Takeda Shareholders Back Shire Merger

Chances that the group of Takeda minority shareholders opposing the Japanese drug maker’s planned acquisition of rival Shire will succeed in blocking the deal appear to be low, local sources told CTFN.featured

Akorn v. Fresenius: Notes from Day Four of the Trial

Corrected for witness name in updates beginning 12:29pm … Day 4 of the trial began with the lawyer for Fresenius continuing a heated cross-examination of the attorney who conducted Akorn’s internal investigation into the fraudulentfeatured

Akorn v. Fresenius Trial: Day 2 Updates

Day two of the Akorn v. Fresenius trial began with a Fresenius attorney working to impeach Monday’s testimony of a compliance expert who testified on behalf of Akorn thatfeatured

Updates from the Akorn v. Fresenius Trial

A senior executive from Akorn downplayed its data integrity dispute with federal regulators this morning during the first day of a trial over Fresenius’ attempt to terminate itsfeatured

Takeda Dissident Shareholders Raise Concerns over Shire Pipeline

A group of minority shareholders of Japanese drug company Takeda will carry out a review of Shire’s R&D pipeline to prove that even the most promising business areas wouldfeatured

Abbvie Dutch Tender Looks More Like Amgen than Whirlpool

While results of the Whirlpool and CIT Dutch auctions highlight that trading Dutch auctions can be tricky for investors, results of the Abbvie Dutch auction are unlikely to be asfeatured

Abbvie Dutch Tender Could Follow Amgen Precedent

With minimum proration of just 4.1%, the current Abbvie modified Dutch tender auction does not appear to offer a meaningful arbitrage opportunity compared to situations where a company may befeatured

Top Chinese Pharma Companies Seeking Deals in the US

With additional reporting by Diane Alter – The top 20 Chinese pharmaceutical companies are seeking US acquisitions, taking advantage of a lull in healthcare M&A because of regulatory uncertainty to find bargains, said a sourcefeatured


Interested in a trial?

Simply fill out the form below and one of our representatives will be in touch.